{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:03:52Z","timestamp":1777525432117,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1888,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/jto.0b013e3181f20d9a","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T11:29:35Z","timestamp":1285068575000},"page":"S313-S317","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S4","title":["The Multidisciplinary Approach to Thymoma: Combining Molecular and Clinical Approaches"],"prefix":"10.1016","volume":"5","author":[{"given":"Nicole G.","family":"Chau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181f20d9a_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib2","series-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart","year":"2004"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1309\/CAV8RNU5TKNACKNC","article-title":"Thymoma classification: current status and future trends","volume":"125","author":"Suster","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.hoc.2008.03.007","article-title":"Molecular pathology of thymic epithelial neoplasms","volume":"22","author":"Kuhn","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib5","first-page":"3708","article-title":"Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas","volume":"63","author":"Inoue","year":"2003","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib6","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9440(10)64536-1","article-title":"Recurrent genetic aberrations in thymoma and thymic carcinoma","volume":"157","author":"Zettl","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ijc.10624","article-title":"Gene expression analysis of human thymoma correlates with tumor stage","volume":"101","author":"Sasaki","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bjc.6690773","article-title":"Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience","volume":"81","author":"Berruti","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib12","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib14","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"issue":"suppl","key":"10.1097\/JTO.0b013e3181f20d9a_bib15","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/jco.2008.26.15_suppl.8018","article-title":"A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99","volume":"20","author":"Lemma","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib16","doi-asserted-by":"crossref","unstructured":"Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. In: 2006 ASCO Annual Meeting; 2006:2006.","DOI":"10.1200\/jco.2006.24.18_suppl.7079"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/cncr.22404","article-title":"Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia","volume":"109","author":"Liu","year":"2007","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s005950300018","article-title":"Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma","volume":"33","author":"Sasaki","year":"2003","journal-title":"Surg Today"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","article-title":"Tyrosine kinase receptor expression in thymomas","volume":"130","author":"Henley","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2006.07.003","article-title":"Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas","volume":"248","author":"Meister","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib23","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib24","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdn388","article-title":"Response of malignant thymoma to erlotinib","volume":"19","author":"Christodoulou","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2006.01.009","article-title":"Thymic carcinoma with epidermal growth factor receptor gene mutations","volume":"52","author":"Yamaguchi","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2559.2003.01663.x","article-title":"Expression of apoptosis-related markers and HER-2\/neu in thymic epithelial tumours","volume":"43","author":"Pan","year":"2003","journal-title":"Histopathology"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib30","first-page":"1621","article-title":"Aberrant methylation: common in thymic carcinomas, rare in thymomas","volume":"14","author":"Suzuki","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.128.1.140","article-title":"Immunohistochemical KIT (CD117) expression in thymic epithelial tumors","volume":"128","author":"Nakagawa","year":"2005","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib33","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib35","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1200\/JCO.2006.08.8963","article-title":"Dasatinib induces a response in malignant thymoma","volume":"24","author":"Chuah","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib36","doi-asserted-by":"crossref","first-page":"14665","DOI":"10.1200\/jco.2008.26.15_suppl.14665","article-title":"Phase II study of imatinib in patients with WHO B3 and C thymomas","volume":"26","author":"Giaccone","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib37","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib38","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"10.1097\/JTO.0b013e3181f20d9a_bib41","article-title":"Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies","volume":"27","author":"Giaccone","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib42","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.3530","article-title":"A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors","volume":"27","author":"Brunetto","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann Anat"},{"issue":"suppl","key":"10.1097\/JTO.0b013e3181f20d9a_bib44","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1097\/JTO.0b013e3181f20d9a_bib45","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1200\/jco.2008.26.15_suppl.3599","article-title":"A phase I dose escalation and pharmacokinetic study of intravenous aflibercept (VEGF trap) plus docetaxel in patients with advanced solid tumors: Preliminary results","volume":"28","author":"Isambert","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/02841860802495362","article-title":"Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma","volume":"48","author":"Azad","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib47","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-08-2196","article-title":"Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas","volume":"15","author":"Stewart","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f20d9a_bib48","unstructured":"Kim ES, Herbst RS, Lee JL, et al. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer. In: 2010 AACR Annual Meeting, Washington Convention Center, 2010. Abstr no. LB1."}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415326228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415326228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T10:32:03Z","timestamp":1636540323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415326228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S1556086415326228"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181f20d9a","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}